Profil:
Selvita SAPublikacja: 2025-09-18 07:39
Selvita pharma backlog for 2025 amounts to PLN 334 mln, up 6 pct y/y
Pharma firm Selvita's backlog for 2025 amounts to PLN 334 million (EUR 71 mln), which is 6 percent higher than at the same time last year, the company said in a market filing.
It was noted that the stabilization of market sentiment observed since the turn of the second and third quarter enabled an increase in sales dynamics. The backlog for the second half of the year is 7 percent lower than a year ago, compared to a negative 22 percent dynamic in May.
PLN mln
The reported results exclude EBITDA from the incentive program. The reported EBITDA for the second quarter of 2025 amounted to PLN 15.4 million (EUR 3.3 mln).
| 2Q2025 | results | consensus | difference | y/y | q/q | YTD 2025 | y/y |
| Revenues | 95.3 | 92.6 | 2.9% | 17.7% | 4.5% | 186.6 | 17.8% |
| EBITDA adj. | 16.0 | 14.3 | 11.9% | 105.1% | 7.4% | 30.9 | 58.5% |
| EBIT | 1.6 | 1.0 | 63.3% | - | - | 1.9 | - |
| Attrib. net profit | -4.6 | -2.9 | - | - | - | -5.6 | - |
| EBITDA adj. margin | 16.8% | 15.5% | 1.33 | 7.16 | 0.45 | 16.56% | 4.25 |
| EBIT margin | 1.7% | 0.9% | 0.81 | 9.46 | 1.35 | 1.02% | 6.32 |
| net margin | -4.8% | -2.7% | -2.16 | 7.52 | -3.73 | -3.00% | 4.64 |
doa/ nl/